These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29997223)

  • 1. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
    Morelli E; Biamonte L; Federico C; Amodio N; Di Martino MT; Gallo Cantafio ME; Manzoni M; Scionti F; Samur MK; Gullà A; Stamato MA; Pitari MR; Caracciolo D; Sesti S; Frandsen NM; Rossi M; Neri A; Fulciniti M; Munshi NC; Tagliaferri P; Tassone P
    Blood; 2018 Sep; 132(10):1050-1063. PubMed ID: 29997223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
    Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
    PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
    Gullà A; Di Martino MT; Gallo Cantafio ME; Morelli E; Amodio N; Botta C; Pitari MR; Lio SG; Britti D; Stamato MA; Hideshima T; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
    Clin Cancer Res; 2016 Mar; 22(5):1222-33. PubMed ID: 26527748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
    Monoe Y; Jingushi K; Kawase A; Hirono T; Hirose R; Nakatsuji Y; Kitae K; Ueda Y; Hase H; Abe Y; Adachi J; Tomonaga T; Tsujikawa K
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma.
    Yang Y; Li F; Saha MN; Abdi J; Qiu L; Chang H
    Clin Cancer Res; 2015 May; 21(10):2399-411. PubMed ID: 25724519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.
    Di Martino MT; Gullà A; Cantafio ME; Lionetti M; Leone E; Amodio N; Guzzi PH; Foresta U; Conforti F; Cannataro M; Neri A; Giordano A; Tagliaferri P; Tassone P
    Oncotarget; 2013 Feb; 4(2):242-55. PubMed ID: 23479461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
    Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
    Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
    [No Abstract]   [Full Text] [Related]  

  • 8. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes.
    Inomata M; Tagawa H; Guo YM; Kameoka Y; Takahashi N; Sawada K
    Blood; 2009 Jan; 113(2):396-402. PubMed ID: 18941111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
    Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
    Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers.
    Mignacca L; Saint-Germain E; Benoit A; Bourdeau V; Moro A; Ferbeyre G
    Cytokine; 2016 Jun; 82():80-6. PubMed ID: 26841929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.
    Chen L; Li C; Zhang R; Gao X; Qu X; Zhao M; Qiao C; Xu J; Li J
    Cancer Lett; 2011 Oct; 309(1):62-70. PubMed ID: 21664042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma.
    Wu C; Ruan T; Liu W; Zhu X; Pan J; Lu W; Yan C; Tao K; Zhang W; Zhang C
    Curr Pharm Des; 2018; 24(5):564-575. PubMed ID: 28322158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma.
    Ogawa H; Nakashiro KI; Tokuzen N; Kuribayashi N; Goda H; Uchida D
    Cancer Sci; 2020 May; 111(5):1645-1651. PubMed ID: 32086979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.
    Manier S; Powers JT; Sacco A; Glavey SV; Huynh D; Reagan MR; Salem KZ; Moschetta M; Shi J; Mishima Y; Roche-Lestienne C; Leleu X; Roccaro AM; Daley GQ; Ghobrial IM
    Leukemia; 2017 Apr; 31(4):853-860. PubMed ID: 27773931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
    Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
    Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.
    Ronca R; Ghedini GC; Maccarinelli F; Sacco A; Locatelli SL; Foglio E; Taranto S; Grillo E; Matarazzo S; Castelli R; Paganini G; Desantis V; Cattane N; Cattaneo A; Mor M; Carlo-Stella C; Belotti A; Roccaro AM; Presta M; Giacomini A
    Cancer Res; 2020 Jun; 80(11):2340-2354. PubMed ID: 32094301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
    Wu Y; Wang H
    J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of LncRNA ANRIL mediated by miR-411-3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1α.
    Wang M; Zhao HY; Zhang JL; Wan DM; Li YM; Jiang ZX
    Exp Cell Res; 2020 Nov; 396(1):112280. PubMed ID: 32961145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.
    Zhao Y; Zhao L; Ischenko I; Bao Q; Schwarz B; Nieß H; Wang Y; Renner A; Mysliwietz J; Jauch KW; Nelson PJ; Ellwart JW; Bruns CJ; Camaj P
    Target Oncol; 2015 Dec; 10(4):535-48. PubMed ID: 25639539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells.
    Palagani A; Op de Beeck K; Naulaerts S; Diddens J; Sekhar Chirumamilla C; Van Camp G; Laukens K; Heyninck K; Gerlo S; Mestdagh P; Vandesompele J; Berghe WV
    PLoS One; 2014; 9(12):e113842. PubMed ID: 25474406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.